Search

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Session information—May 15, 2025

Topic'Optimizing vaccination strategies for chemotherapy patients: Bridging gaps in preventive care. '

Speaker detailsVerena PetzerSince February 2025, Dr Verena Petzer has been a specialist in internal medicine for hematology and oncology at the Medical University of Innsbruck in Austria.

Read more

SWG Educational Activities

Recruitment trialsRecruitment is underway for the following trials:

Trial on precision hematology: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2); ClinicalTrials.

Read more

In Memoriam Professor Emeritus Michel Symann

Dear Colleagues,

My dear friend Professor Emeritus Michel Symann passed away on April 23, 2023 at the age of 81.

Read more

Highlights of Past EHA (HOPE) Latin America 2020

EHA and the Argentinian Society of Hematology (SAH) are very happy to announce that the Highlights of Past EHA (HOPE) Latin America 2020 will take place on November 13, 2020 in a virtual format.

Read more

Highlights of Past EHA (HOPE) Asia 2021

For the third edition of the Highlights of Past EHA (HOPE) Asia, EHA will organize a truly regional meeting by collaborating simultaneously with our hematology partners from the region.

Read more

Highlights from the SWG

SWG session at EHA2023The EHA2023 Congress was held in Frankfurt, Germany, in June 2023. As part of this event, the SWG held a session on Saturday, June 10, 2023. Title‘Stem cells: Clonal and mutational dynamics of hematopoietic stem cells.

Read more